Trial Profile
A Phase II Study of Neoadjuvant rFowlpox-PSA (L155)-TRICOM (Prostvac-F/TRICOM) in Combination With rVaccinia-PSA (L155)-TRICOM (Prostvac-V/TRICOM) in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2023
Price :
$35
*
At a glance
- Drugs Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 01 May 2023 The boosting schedule was amended mid-trial to weeks 3, 5 and9 to allow for earlier surgeries, as per results presented at the 118th Annual Meeting of the American Urological Association.
- 01 May 2023 Results (Between 2014-2016, n=26) assessing the surgical safety and feasibility outcomes of patients investigating the neoadjuvant use of this vaccinetherapy in patients with localized PCa, presented at the 118th Annual Meeting of the American Urological Association.
- 05 Jun 2018 Results assessing the effect of galvacirepvec/rilimogene glafolivec on intra/peritumoral immune infiltrate, presented at the 54th Annual Meeting of the American Society of Clinical Oncology